First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
{{output}}
Background & aims: RG6346 is an N-acetyl-D-galactosamine (GalNAc)-conjugated, double-stranded RNA interference agent targeting the HBV genome S-region. We investigated the safety, tolerability, pharmacokinetics, and pharmacodynam... ...
